WallStSmart

Encompass Health Corp (EHC)vsMarvell Technology Group Ltd (MRVL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Marvell Technology Group Ltd generates 44% more annual revenue ($8.72B vs $6.07B). MRVL leads profitability with a 29.0% profit margin vs 10.0%. EHC appears more attractively valued with a PEG of 0.41. EHC earns a higher WallStSmart Score of 75/100 (B+).

EHC

Strong Buy

75

out of 100

Grade: B+

Growth: 8.0Profit: 7.5Value: 6.7Quality: 6.0
Piotroski: 6/9Altman Z: 2.12

MRVL

Buy

55

out of 100

Grade: C

Growth: 6.0Profit: 7.0Value: 3.7Quality: 8.0
Piotroski: 5/9Altman Z: 1.90
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EHCSignificantly Overvalued (-57.0%)

Margin of Safety

-57.0%

Fair Value

$72.27

Current Price

$104.01

$31.74 premium

UndervaluedFair: $72.27Overvalued

Intrinsic value data unavailable for MRVL.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EHC4 strengths · Avg: 8.8/10
PEG RatioValuation
0.4110/10

Growing faster than its price suggests

Return on EquityProfitability
24.2%9/10

Every $100 of equity generates 24 in profit

P/E RatioValuation
17.4x8/10

Attractively priced relative to earnings

EPS GrowthGrowth
30.3%8/10

Earnings expanding 30.3% YoY

MRVL4 strengths · Avg: 9.0/10
Market CapQuality
$264.11B10/10

Mega-cap, among the largest globally

Profit MarginProfitability
29.0%9/10

Keeps 29 of every $100 in revenue as profit

Debt/EquityHealth
0.299/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
27.6%8/10

Revenue surging 27.6% year-over-year

Areas to Watch

EHC1 concerns · Avg: 3.0/10
Debt/EquityHealth
1.113/10

Elevated debt levels

MRVL4 concerns · Avg: 3.5/10
PEG RatioValuation
1.644/10

Expensive relative to growth rate

Price/BookValuation
18.7x4/10

Trading at 18.7x book value

Altman Z-ScoreHealth
1.904/10

Grey zone — moderate risk

P/E RatioValuation
104.0x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : EHC

The strongest argument for EHC centers on PEG Ratio, Return on Equity, P/E Ratio. PEG of 0.41 suggests the stock is reasonably priced for its growth.

Bull Case : MRVL

The strongest argument for MRVL centers on Market Cap, Profit Margin, Debt/Equity. Profitability is solid with margins at 29.0% and operating margin at 14.5%. Revenue growth of 27.6% demonstrates continued momentum.

Bear Case : EHC

The primary concerns for EHC are Debt/Equity.

Bear Case : MRVL

The primary concerns for MRVL are PEG Ratio, Price/Book, Altman Z-Score. A P/E of 104.0x leaves little room for execution misses.

Key Dynamics to Monitor

EHC profiles as a value stock while MRVL is a growth play — different risk/reward profiles.

MRVL carries more volatility with a beta of 2.25 — expect wider price swings.

MRVL is growing revenue faster at 27.6% — sustainability is the question.

MRVL generates stronger free cash flow (483M), providing more financial flexibility.

Bottom Line

EHC scores higher overall (75/100 vs 55/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Encompass Health Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Encompass Health Corporation offers in-home and post-acute health care services in the United States. The company is headquartered in Birmingham, Alabama.

Marvell Technology Group Ltd

TECHNOLOGY · SEMICONDUCTORS · USA

Marvell Technology, Inc. designs, develops, and sells analog, mixed-signal, digital signal processing, and integrated and independent integrated circuits. The company is headquartered in Wilmington, Delaware.

Visit Website →

Want to dig deeper into these stocks?